NO160135C - Analogifremgangsmaate ved fremstilling av terapeutisk aktive 4-amino-alkyl-2(3h)-indoloner. - Google Patents

Analogifremgangsmaate ved fremstilling av terapeutisk aktive 4-amino-alkyl-2(3h)-indoloner.

Info

Publication number
NO160135C
NO160135C NO834485A NO834485A NO160135C NO 160135 C NO160135 C NO 160135C NO 834485 A NO834485 A NO 834485A NO 834485 A NO834485 A NO 834485A NO 160135 C NO160135 C NO 160135C
Authority
NO
Norway
Prior art keywords
indolones
amino
alkyl
preparation
therapeutic active
Prior art date
Application number
NO834485A
Other languages
English (en)
Other versions
NO834485L (no
NO160135B (no
Inventor
Gregory Gallagher Jr
Original Assignee
Smithkline Beckman Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23776840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO160135(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beckman Corp filed Critical Smithkline Beckman Corp
Publication of NO834485L publication Critical patent/NO834485L/no
Publication of NO160135B publication Critical patent/NO160135B/no
Publication of NO160135C publication Critical patent/NO160135C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
NO834485A 1982-12-07 1983-12-06 Analogifremgangsmaate ved fremstilling av terapeutisk aktive 4-amino-alkyl-2(3h)-indoloner. NO160135C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/447,564 US4452808A (en) 1982-12-07 1982-12-07 4-Aminoalkyl-2(3H)-indolones

Publications (3)

Publication Number Publication Date
NO834485L NO834485L (no) 1984-06-08
NO160135B NO160135B (no) 1988-12-05
NO160135C true NO160135C (no) 1989-03-15

Family

ID=23776840

Family Applications (2)

Application Number Title Priority Date Filing Date
NO834485A NO160135C (no) 1982-12-07 1983-12-06 Analogifremgangsmaate ved fremstilling av terapeutisk aktive 4-amino-alkyl-2(3h)-indoloner.
NO1999011C NO1999011I1 (no) 1982-12-07 1999-06-18 Ropinirole

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO1999011C NO1999011I1 (no) 1982-12-07 1999-06-18 Ropinirole

Country Status (27)

Country Link
US (1) US4452808A (no)
EP (1) EP0113964B1 (no)
JP (1) JPS59112964A (no)
KR (1) KR910001042B1 (no)
AU (1) AU560170B2 (no)
BR (1) BR1100036A (no)
CA (1) CA1208650A (no)
CY (1) CY1497A (no)
CZ (1) CZ398191A3 (no)
DE (1) DE3367090D1 (no)
DK (1) DK156514C (no)
DZ (1) DZ587A1 (no)
EG (1) EG16556A (no)
ES (2) ES527827A0 (no)
FI (1) FI77849C (no)
GR (1) GR79121B (no)
HK (1) HK82089A (no)
IE (1) IE56347B1 (no)
IL (1) IL70311A (no)
LU (1) LU90097I2 (no)
NL (1) NL970005I2 (no)
NO (2) NO160135C (no)
NZ (1) NZ206344A (no)
PH (1) PH22067A (no)
PT (1) PT77739B (no)
ZA (1) ZA839094B (no)
ZW (1) ZW25883A1 (no)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588740A (en) * 1982-12-07 1986-05-13 Smithkline Beckman Corporation Pharmaceutical methods using 4-aminoalkyl-2(3H)-indolones
US4657929A (en) * 1983-10-25 1987-04-14 Fisons Plc Compounds
US4554284A (en) * 1984-09-12 1985-11-19 Smithkline Beckman Corporation 7-(2-Aminoethyl)-1,3-benzthia- or oxa-zol-2(3H)-ones
GB8621040D0 (en) * 1986-08-30 1986-10-08 Smith Kline French Lab Process
GB8712073D0 (en) * 1987-05-21 1987-06-24 Smith Kline French Lab Medicament
GB8714371D0 (en) * 1987-06-19 1987-07-22 Smith Kline French Lab Process
GB9008605D0 (en) * 1990-04-17 1990-06-13 Smith Kline French Lab Process
GB9015095D0 (en) * 1990-07-09 1990-08-29 Smith Kline French Lab Therapeutic method
IE914003A1 (en) * 1990-11-20 1992-05-20 Astra Pharma Prod Biologically Active Amines
JPH07506823A (ja) * 1992-05-18 1995-07-27 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 記憶障害，性的機能不全およびパーキンソン氏病の治療のためのインドロン誘導体の使用
GB9300309D0 (en) * 1993-01-08 1993-03-03 Smithkline Beecham Plc Process
TW356468B (en) * 1995-09-15 1999-04-21 Astra Pharma Prod Benzothiazolone compounds useful as beta2-adrenoreceptor and dopamine DA2 receptor agonists process for preparing same and pharmaceutical compositions containing same
US5807570A (en) * 1995-09-29 1998-09-15 Cygnus, Inc. Transdermal administration of ropinirole and analogs thereof
GB9526511D0 (en) * 1995-12-23 1996-02-28 Astra Pharma Prod Pharmaceutically active compounds
CN1234024A (zh) * 1996-08-27 1999-11-03 美国家用产品公司 4－氨基乙氧基吲哚衍生物
ZA992670B (en) * 1998-04-13 2000-10-12 American Home Prod 4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists.
US6218421B1 (en) * 1999-07-01 2001-04-17 Smithkline Beecham P.L.C. Method of promoting smoking cessation
AR030557A1 (es) 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US6277875B1 (en) * 2000-07-17 2001-08-21 Andrew J. Holman Use of dopamine D2/D3 receptor agonists to treat fibromyalgia
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
WO2002069974A1 (en) * 2001-03-05 2002-09-12 Andrew Holman Administration of sleep restorative agents
FR2821843B1 (fr) * 2001-03-12 2003-05-09 Servier Lab Nouveaux derives d'isoindoloindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20030068356A1 (en) * 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
JP4630665B2 (ja) * 2002-09-13 2011-02-09 モタック・ニューロサイエンス・リミテッド ２，３−ベンゾジアゼピンによる基底核関連運動障害の治療
CA2499200A1 (en) * 2002-09-17 2004-04-01 Motac Neuroscience Limited Use of compounds in the treatment of dyskinesia
ES2237307B1 (es) * 2003-10-14 2006-11-01 Urquima, S.A. Procedimiento para la preparacion de ropinirol.
WO2005074387A2 (en) * 2003-12-30 2005-08-18 Sun Pharmaceutical Industries Limited Novel crystal forms of 4-[2-di-n-propylamino)ethyl]-2 (3h)- indolone hydrochloride
US7378439B2 (en) * 2004-01-20 2008-05-27 Usv, Ltd. Process for the preparation of 4-(2-dipropylaminoethyl)-1,3-dihydro-2H-indol-2-one hydrochloride
WO2005105741A1 (en) * 2004-02-11 2005-11-10 Sun Pharmaceutical Industries Limited Substantially pure 4-[2-(di-n-propylamino)ethyl]-2(3h)-indolone hydrochloride
WO2005080333A1 (en) * 2004-02-19 2005-09-01 Torrent Pharmaceuticals Ltd Process for purification of ropinirole
DK1751106T3 (da) * 2004-05-11 2009-03-09 Egis Gyogyszergyar Nyrt Piperazinderivater af alkyloxindoler
HUP0400953A3 (en) * 2004-05-11 2008-02-28 Egis Gyogyszergyar Nyilvanosan Piperazine derivatives of alkyl-oxindoles, pharmaceutical compositions containing them, process for producing them and their use
US20050267096A1 (en) * 2004-05-26 2005-12-01 Pfizer Inc New indazole and indolone derivatives and their use pharmaceuticals
US20050288270A1 (en) * 2004-05-27 2005-12-29 Pfizer Inc New aminopyridine derivatives and their use as pharmaceuticals
WO2006100588A1 (en) * 2005-03-21 2006-09-28 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
CN100457711C (zh) * 2005-06-27 2009-02-04 上海奥博生物医药技术有限公司 2-甲基-3-硝基苯基烷基胺衍生物或其盐的制备方法
WO2007010557A2 (en) * 2005-07-22 2007-01-25 Ind-Swift Laboratorie Limted Process for the preparation of highly pure ropinirole
BRPI0709184A2 (pt) 2006-03-29 2011-06-28 Alembic Ltd processo para a purificação de cloridrato de ropinirol
BRPI0709769B8 (pt) * 2006-04-06 2021-05-25 Nupathe Inc implantes biodegradáveis para o tratamento de estados associados à dopamina
US20070254941A1 (en) * 2006-04-21 2007-11-01 Glenmark Pharmaceuticals Limited Subtantially pure ropinirole hydrochloride, polymorphic form of ropinirole and process for their preparation
CN100457732C (zh) * 2006-05-25 2009-02-04 药源药物化学（上海）有限公司 罗匹尼罗的制备方法
TW200815045A (en) * 2006-06-29 2008-04-01 Jazz Pharmaceuticals Inc Pharmaceutical compositions of ropinirole and methods of use thereof
WO2008001204A2 (en) * 2006-06-29 2008-01-03 Antares Pharma Ipl Ag Transdermal compositions of pramipexole having enhanced permeation properties
CA2686394A1 (en) * 2007-05-11 2008-11-20 Santen Pharmaceutical Co., Ltd. Prophylactic or therapeutic agent for posterior ocular disease comprising non-ergot selective d2 receptor agonist as active ingredient
US20090076124A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched ropinirole
US20090247537A1 (en) * 2008-03-25 2009-10-01 William Dale Overfield Methods for preventing or treating bruxism using dopaminergic agents
CN101574341B (zh) * 2008-05-05 2012-12-19 北京德众万全医药科技有限公司 一种罗匹尼罗的口服固体药物组合物
US20110195117A1 (en) * 2008-09-01 2011-08-11 Lupin Limited Controlled release compositions of ropinirole
CA2738414C (en) 2008-09-29 2014-05-27 Wockhardt Research Centre Extended release dosage form of ropinirole
US20100130582A1 (en) * 2008-11-24 2010-05-27 Auspex Pharmaceuticals, Inc. Indolinone modulators of dopamine receptor
KR101709361B1 (ko) 2009-05-21 2017-02-22 히사미쓰 세이야꾸 가부시키가이샤 경피 흡수 제제
WO2011072704A1 (en) * 2009-12-16 2011-06-23 Pharmathen S.A. Process for the preparation of ropinirole and salts thereof
CA2793571C (en) 2010-04-30 2015-10-13 Teikoku Pharma Usa, Inc. Propynylaminoindan transdermal compositions
CN101891641B (zh) * 2010-07-27 2015-06-10 北京华禧联合科技发展有限公司 盐酸罗匹尼罗关键中间体的稳定形态及其制备
TWI537274B (zh) 2011-03-14 2016-06-11 橘生藥品工業股份有限公司 新穎之八氫噻吩并喹啉衍生物、含有其之醫藥組成物及該等之用途
CN103476404B (zh) 2011-03-24 2017-09-29 帝国制药美国公司 包含活性剂层和活性剂转化层的透皮组合物
JP5913614B2 (ja) 2011-11-09 2016-04-27 テイコク ファーマ ユーエスエー インコーポレーテッド 皮膚新生物の処置方法
KR20150059177A (ko) 2012-11-02 2015-05-29 테이코쿠 팔마 유에스에이, 인코포레이티드 프로피닐아미노인단 경피 조성물
WO2014092006A1 (ja) 2012-12-10 2014-06-19 キッセイ薬品工業株式会社 新規なオクタヒドロピリドキナゾリン誘導体、それを含有する医薬組成物およびそれらの用途
US9155695B2 (en) 2013-03-14 2015-10-13 Medtronic, Inc. Injectable ropinirole compositions and methods for making and using same
US10961194B2 (en) 2017-06-16 2021-03-30 Zhejiang Huahai Licheng Pharmaceutical Co., Ltd. Method for purifying ropinirole hydrochloride
CN115466209A (zh) * 2022-09-29 2022-12-13 南通大学 一种罗匹尼罗环戊烷并吲哚酮杂质的合成方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA895875A (en) * 1972-03-21 Bourdais Jacques Mercapto indole derivatives
US3573310A (en) * 1967-09-28 1971-03-30 Miles Lab 1-substituted derivatives of 2-indolinone
JPS5840539B2 (ja) * 1976-03-31 1983-09-06 大塚製薬株式会社 α−置換アミノアルカノイルオキシインド−ル誘導体
JPS5825673B2 (ja) * 1976-03-31 1983-05-28 大塚製薬株式会社 オキシインド−ル誘導体
JPS5919537B2 (ja) * 1976-08-02 1984-05-07 大塚製薬株式会社 オキシインド−ル誘導体
US4317944A (en) * 1980-08-15 1982-03-02 General Electric Company Preparation of 2,2-bis(4-hydroxyphenyl) propane
US4314944A (en) * 1980-08-22 1982-02-09 Smithkline Corporation 4-Aminoalkyl-7-hydroxy-2(3H)-indolones

Also Published As

Publication number Publication date
PT77739B (en) 1986-03-27
NO834485L (no) 1984-06-08
ZA839094B (en) 1985-02-27
LU90097I2 (fr) 1997-07-16
GR79121B (no) 1984-10-02
FI77849B (fi) 1989-01-31
NO1999011I1 (no) 1999-06-18
EG16556A (en) 1989-01-30
KR840006963A (ko) 1984-12-04
CZ398191A3 (en) 1993-02-17
NL970005I1 (nl) 1997-04-01
ES8604143A1 (es) 1986-01-16
EP0113964A1 (en) 1984-07-25
JPS59112964A (ja) 1984-06-29
NZ206344A (en) 1987-03-31
PT77739A (en) 1983-12-01
IL70311A (en) 1986-11-30
IL70311A0 (en) 1984-02-29
JPH0150703B2 (no) 1989-10-31
DK562183A (da) 1984-06-08
ES8600239A1 (es) 1985-10-01
HK82089A (en) 1989-10-20
ES527827A0 (es) 1985-10-01
DZ587A1 (fr) 2004-09-13
ES543593A0 (es) 1986-01-16
EP0113964B1 (en) 1986-10-22
DE3367090D1 (de) 1986-11-27
FI834421A (fi) 1984-06-08
BR1100036A (pt) 2000-01-11
AU2158583A (en) 1984-06-14
NO160135B (no) 1988-12-05
IE56347B1 (en) 1991-07-03
PH22067A (en) 1988-05-20
DK562183D0 (da) 1983-12-06
KR910001042B1 (ko) 1991-02-21
IE832866L (en) 1984-06-07
FI77849C (fi) 1989-05-10
NL970005I2 (nl) 1997-10-01
AU560170B2 (en) 1987-04-02
CA1208650A (en) 1986-07-29
ZW25883A1 (en) 1984-04-18
US4452808A (en) 1984-06-05
CY1497A (en) 1990-02-16
FI834421A0 (fi) 1983-12-02
DK156514C (da) 1990-03-12
DK156514B (da) 1989-09-04

Similar Documents

Publication Publication Date Title
NO160135C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 4-amino-alkyl-2(3h)-indoloner.
NO158021C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktivt d-fenylalanyl-l-prolyl-l-argininaldehydsulfat.
NO160521C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 13alfa- alkylgonaner.
NO161065C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 2-azetidinoner.
NO163691C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive n-acryl-piperazinalkanamider.
NO158099C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive karbostyrilderivater.
NO156864B (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive piperinderivater.
NO166320C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive tetrazolderivater.
NO156693C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 10-propynylsteroider.
NO157146C (no) Analogifremgangsmaate ved fremstilling av terapeutisk, aktive derivater av morfolinyl-daunorbicin og morfolinyl-doksorubicin.
NO162858C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive thiazolidinderivater.
NO161679C (no) Analogifremgangsm te ved fremstilling av terapeutisk aktive steroider.
NO158183C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive imidazolylfenylamidiner.
NO158534C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive fenoksyalkylkarboksylsyrederivater.
NO163693C (no) Fremgangsmaate for fremstilling av terapeutisk aktive forbindelser av platina.
NO159528C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive aminoguanidinderivater.
NO165400C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive cefemforbindelser.
NO157538C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive benzothiazolsufonamidderivater.
NO160079C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive cefem-derivater.
NO158739C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-piperazinopyrimidinderivater.
NO160511C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive fenyl-cyklo-butanderivater.
NO161313C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive fluorallylaminderivater.
NO158673C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive azurenderivater.
NO811346L (no) Fremgangsmaate ved fremstilling av terapeutisk aktive adenosin-derivater.
NO164415C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 5-acyl-2-(1h)-pyridinoner.